The Global Thrombosis Drugs Market Is Expected To Witness A CAGR Of 9.5% To Reach Revenue Of $38,901.2 Million By 2024
Bangalore, India, January 1, 2019: With its recently published study “Thrombosis Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024”, Infoholic Research forecasts that the Global Thrombosis Drugs Market will continue to grow, owing to the increasing burden of cardiovascular disease & trauma cases and upsurge in the geriatric & obese population. The increase in the launch of new drugs in the market and R&D programs to develop new drugs provide an opportunity for improved and effective treatment for the condition, which is anticipated to support the market growth during the forecast period.
Get a Sample Copy of the Report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=12610
The Thrombosis Drugs Market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor segment occupied a significant market share in 2017 and is anticipated to grow at a high CAGR during the forecast period. The increase in the preference for oral anticoagulant drugs usage is likely to boost this segment during the forecast period.
On the basis of indication, the thrombosis drugs market is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment occupied a major market share in 2017 and is expected to grow at a high CAGR during the forecast period. A large patient pool with pulmonary embolism condition along with an increased focus on developing low-cost drugs is likely to propel the market growth during the forecast years.
Access Full Report Summary @ https://www.infoholicresearch.com/report/tissue-banking-market
“The global thrombosis drugs market is growing steadily, and key vendors are focusing on agreements, collaborations, and new launches to increase their revenue and strengthen their product portfolio. For instance, in January 2017, AstraZeneca signed a research collaboration with APT Therapeutics, focused on the development of APT’s lead human recombinant apyrase therapy APT102 for the treatment of thrombotic disorders. In addition, the growing prevalence of cardiovascular disease population is expected to provide a better opportunity for the increase in the demand for thrombosis drugs.” – Arpitha Shetty, Research Analyst, Infoholic Research
Key Insights of the Report Include
- By Drug Class
- Factor Xa Inhibitor
- Low Molecular Weight Heparin
- P2Y12 Platelet Inhibitor
- By Indication
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- By Regions
- North America
- Asia Pacific
- Rest of the World
- Industry outlook: Market trends, drivers, restraints, and opportunities
Ms. Sunanda Ganguli
Infoholic Research LLP